NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis
NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has achieved a groundbreaking milestone in North America. The company proudly announced that it has successfully performed the first-ever injection of Arthrosamid® on the continent at its Mississauga, Ontario clinic. This development marks a significant advancement in the treatment of knee osteoarthritis (OA) and offers new hope to millions of Canadians suffering from the debilitating condition.
Arthrosamid®, an innovative hydrogel injection, has gained recognition in Europe as a long-lasting, non-surgical solution for knee osteoarthritis. Prior to receiving approval from Health Canada, Canadian patients seeking this advanced treatment had to travel abroad, often to European medical centers, to access its benefits. Now, with Arthrosamid® available in Canada, patients have a revolutionary new option that has been shown to provide up to four years of sustained pain relief, improving mobility and enhancing quality of life.
A Game-Changer for Osteoarthritis Treatment in Canada
“This is a major step forward in osteoarthritis treatment options for Canadians,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “It underscores our commitment to providing the best chronic pain care to our patients as we scale up our clinic network and expand our services across Canada. We continue to seek out proven, innovative treatments that leverage our growing market presence and the skills of our healthcare professionals.”
Osteoarthritis is a chronic, degenerative joint disease that affects millions worldwide. In Canada alone, over four million people live with osteoarthritis, with knee OA being one of the most common and painful forms of the disease. The condition not only leads to chronic pain but also severely impacts mobility, independence, and overall quality of life.
According to a report by the Arthritis Society of Canada, the economic burden of arthritis in the country was estimated to be $6.4 billion, accounting for nearly one-third of the total costs associated with musculoskeletal diseases. As populations continue to age, the prevalence of osteoarthritis is expected to rise, intensifying the need for effective, long-lasting treatments that go beyond temporary pain relief.
The Need for Advanced, Long-Lasting Solutions
Traditional non-surgical interventions for knee osteoarthritis typically include painkillers such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and hyaluronic acid injections. While these treatments can offer temporary symptom relief, they do not address the underlying structural issues of the disease, nor do they provide prolonged effectiveness. Additionally, long-term reliance on NSAIDs or corticosteroids can lead to significant side effects, including gastrointestinal issues, cardiovascular risks, and joint deterioration.
Arthrosamid® represents a new frontier in osteoarthritis treatment by addressing these limitations. Unlike conventional injections, Arthrosamid® is composed of a non-biodegradable polyacrylamide hydrogel that integrates with the synovial tissue in the knee joint. This innovative formulation provides long-term cushioning and lubrication, reducing pain and improving joint function without the need for repeated injections every few months.
How Arthrosamid® Works
The mechanism behind Arthrosamid® is unique compared to other injectable therapies. When injected into the knee joint, the hydrogel becomes an integral part of the synovial membrane, offering sustained biomechanical support and pain relief. This long-lasting effect has been demonstrated in clinical trials, with some patients experiencing significant pain reduction for up to four years. This makes Arthrosamid® an attractive option for patients who are either not suitable candidates for knee replacement surgery or wish to delay surgical intervention while maintaining mobility and pain control.
A growing body of clinical evidence supports the safety and efficacy of Arthrosamid®. Studies have shown that patients who receive the injection experience not only significant pain relief but also improved joint function and overall physical well-being. Unlike corticosteroid injections, which often lose effectiveness over time, Arthrosamid® provides a durable solution that enhances patients’ quality of life for an extended period.
NeuPath Health’s Leadership in Chronic Pain Management
NeuPath Health has established itself as a leader in chronic pain management in Canada, operating a network of specialized clinics that provide evidence-based, patient-centered care. The company is committed to integrating the latest medical innovations into its treatment portfolio, ensuring that patients have access to the most effective and advanced pain management solutions available.
By introducing Arthrosamid® to the Canadian market, NeuPath Health reinforces its position at the forefront of medical innovation in chronic pain treatment. The company’s expansion into cutting-edge, minimally invasive therapies aligns with its mission to enhance patient outcomes and reduce the reliance on opioids and other short-term pain management strategies.
Expanding Access to Innovative Osteoarthritis Treatments
As NeuPath Health continues to grow its clinical footprint across Canada, it remains dedicated to providing widespread access to innovative treatments like Arthrosamid®. The company is actively working to ensure that more Canadians can benefit from this groundbreaking therapy, helping them regain mobility and improve their overall well-being.
Patients suffering from knee osteoarthritis who are interested in learning more about Arthrosamid® can consult with NeuPath Health’s team of healthcare professionals to determine if they are suitable candidates for the treatment. With its strong commitment to excellence in pain management, NeuPath Health is poised to make a lasting impact on the lives of osteoarthritis sufferers nationwide.
